About the API
Abaloparatide is an bone-growing (anabolic) agent indicated for the treatment of postmenopausal osteoporosis. It is intended for women at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
In clinical studies in women aged 49 to 86 years, abaloparatide significantly reduced the risk of new vertebral and nonvertebral fractures and increased bone mineral density (BMD) at the lumbar spine, total hip and femoral neck. Age had no effect on the pharmacokinetics of the drug.
It is administered as a once-daily subcutaneous injection.